IFRX

Business Context and Reporting Period

Company: InflaRx N.V.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: February 24, 2021
Reporting Period: Update to Risk Factors for the month of February 2021.
Business Overview: InflaRx is a clinical-stage biopharmaceutical company focused on developing therapies for complement-mediated autoimmune and inflammatory diseases. The company has no approved products and has not generated any revenue from product sales. Its primary focus is the development of vilobelimab (formerly IFX-1), a novel therapeutic antibody targeting C5a inhibition.

Key Financial Metrics

The filing provides historical financial data but does not contain a full income statement or balance sheet for the current period. Key figures disclosed include:

• Net Losses:
  • 2020: €34.0 million
  • 2019: €53.3 million
  • 2018: €29.8 million
• Accumulated Deficit: €168.3 million as of December 31, 2020.
• Cash Flow from Operations:
  • 2020: Used €37.4 million in net cash.
  • 2019: Used €43.2 million in net cash.
• Liquidity: Management believes existing cash, cash equivalents, and marketable securities will fund operations for at least the next 18 months. No committed external funding sources exist.
• Revenue: Zero. The company has not commercialized any products.
• Debt: The filing does not disclose specific debt figures, noting only the need for substantial additional funding.

Material Changes and Operational Status

The filing updates risk factors rather than reporting specific operational changes for February 2021. However, it highlights the following material conditions:

• Clinical Trial Status:
  • Hidradenitis Suppurativa (HS): The Phase IIb SHINE trial (completed 2019) failed to meet its primary endpoint (HiSCR). Post-hoc analyses showed signals of efficacy, but the regulatory pathway remains unclear. The company intends to submit a Special Protocol Assessment (SPA) to the FDA regarding alternative endpoints.
  • Other Indications: Ongoing Phase II trials in anti-neutrophil cytoplasm antibody associated vasculitis (AAV) and Pyoderma Gangraenosum (PG). Slower recruitment in AAV and PG has been observed due to low disease prevalence and the COVID-19 pandemic.
  • COVID-19: A Phase III part of a Phase II/III study in severe COVID-19 is mentioned as part of the development plan.
  • cSCC: A clinical trial and supply agreement with Merck & Co. Inc. has been entered into for cutaneous squamous cell carcinoma (cSCC).
• Capital Requirements: The company expects expenses to increase significantly as it advances clinical trials. It explicitly states it will need substantial additional funding to continue operations and may be forced to delay or eliminate programs if capital cannot be raised.

Guidance, Outlook, and Risks

Outlook and Guidance:

• The company expects to incur significant and increasing losses for the foreseeable future and may never achieve profitability.
• Financial condition and operating results are expected to fluctuate significantly.
• Success depends entirely on the ability to generate revenue from product sales, which requires regulatory approval and commercialization of vilobelimab or future candidates.

• Clinical Failure: High risk of failure in later-stage trials. The failure of the Phase IIb HS trial to meet its primary endpoint raises concerns about the validity of the clinical endpoint and the drug's efficacy.
• Regulatory Uncertainty: No approved therapy inhibits C5a. The regulatory pathway for vilobelimab is novel and uncertain. The FDA may not accept the proposed alternative endpoints for HS.
• Liquidity Risk: Existing cash is insufficient to fund all planned efforts. Failure to raise capital could force the discontinuation of operations.
• Intellectual Property: Risks related to patent validity, enforcement, and potential infringement claims. Certain employees are subject to German law regarding invention rights.
• Corporate Governance: As a Dutch public company, shareholder rights differ from U.S. standards. A "protective foundation" holds rights to issue preferred shares that could deter takeover bids. A pending Dutch bill could introduce a 250-day cooling-off period for board changes during hostile offers.
• Taxation: The company may be classified as a Passive Foreign Investment Company (PFIC) for U.S. tax purposes. Significant net operating loss (NOL) carryforwards exist (€142.0 million in Germany), but their utilization may be limited by ownership changes.

Investor Verification Checklist

• Cash Runway: Verify the exact amount of cash and marketable securities on hand to confirm the "18-month" funding estimate.
• Regulatory Alignment: Confirm the status of the Special Protocol Assessment (SPA) submission to the FDA regarding alternative endpoints for the HS program.
• Capital Raising Plans: Investigate any imminent plans for equity offerings, debt financing, or strategic collaborations to fund the 18-month runway.
• Clinical Recruitment: Monitor enrollment rates for the AAV and PG trials, which have been impacted by the pandemic and disease rarity.
• Merck Collaboration: Review the specific terms and milestones of the clinical trial and supply agreement with Merck for the cSCC indication.
• Post-Hoc Data: Assess the scientific and regulatory weight of the post-hoc analyses from the HS Phase IIb trial versus the primary endpoint failure.